LitAlert ~~ GeneLit.com

    • Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up.
    • Pothuri B, Brodsky AL, Sparano JA, Blank SV, Kim M, Hershman DL, Tiersten A, Kiesel BF, Beumer JH, Liebes L, Muggia F.
    • Cancer Chemother Pharmacol. 2020 Feb 13. doi: 10.1007/s00280-020-04030-2. [Epub ahead of print]
    • A genome-wide association study on medulloblastoma.
    • Dahlin AM, Wibom C, Andersson U, Bybjerg-Grauholm J, Deltour I, Hougaard DM, Scheurer ME, Lau CC, McKean-Cowdin R, Kennedy RJ, Hung LT, Yee J, Margol AS, Barrington-Trimis J, Gauderman WJ, Feychting M, Schüz J, Röösli M, Kjaerheim K; Cefalo Study Group, Januszkiewicz-Lewandowska D, Fichna M, Nowak J, Searles Nielsen S, Asgharzadeh S, Mirabello L, Hjalmars U, Melin B.
    • J Neurooncol. 2020 Feb 13. doi: 10.1007/s11060-020-03424-9. [Epub ahead of print]
    • Myriad Files sPMA With FDA for Test to ID Best Responders to Lynparza, Avastin Combination.
    • [No author given]
    • GenomeWeb. 2020 Feb 11.
    • The incidence of occult ovarian neoplasia and cancer in BRCA1/2 mutation carriers after the bilateral prophylactic salpingo-oophorectomy (PBSO): A single-center prospective study.
    • Rudaitis V, Mikliusas V, Januska G, Jukna P, Mickys U, Janavicius R.
    • Eur J Obstet Gynecol Reprod Biol. 2020 Jan 30;247:26-31. doi: 10.1016/j.ejogrb.2020.01.040. [Epub ahead of print]